FI4090670T3 - Interleukiini-23-reseptorin peptidiestäjiä ja niiden käyttö tulehdussairauksien hoidossa - Google Patents

Interleukiini-23-reseptorin peptidiestäjiä ja niiden käyttö tulehdussairauksien hoidossa

Info

Publication number
FI4090670T3
FI4090670T3 FIEP21741383.0T FI21741383T FI4090670T3 FI 4090670 T3 FI4090670 T3 FI 4090670T3 FI 21741383 T FI21741383 T FI 21741383T FI 4090670 T3 FI4090670 T3 FI 4090670T3
Authority
FI
Finland
Prior art keywords
peptide
pharmaceutically acceptable
acceptable salt
pen
pharmaceutical composition
Prior art date
Application number
FIEP21741383.0T
Other languages
English (en)
Finnish (fi)
Inventor
Chengzao Sun
Brian Troy Frederick
Sandeep Somani
Gregory Thomas Bourne
Raymond Patch
Ashok Bhandari
Raffaele Ingenito
Roberto Costante
Danila Branca
Elisabetta Bianchi
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of FI4090670T3 publication Critical patent/FI4090670T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FIEP21741383.0T 2020-01-15 2021-01-14 Interleukiini-23-reseptorin peptidiestäjiä ja niiden käyttö tulehdussairauksien hoidossa FI4090670T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062961624P 2020-01-15 2020-01-15
PCT/US2021/013463 WO2021146441A1 (en) 2020-01-15 2021-01-14 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
FI4090670T3 true FI4090670T3 (fi) 2025-07-23

Family

ID=76864704

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21741383.0T FI4090670T3 (fi) 2020-01-15 2021-01-14 Interleukiini-23-reseptorin peptidiestäjiä ja niiden käyttö tulehdussairauksien hoidossa

Country Status (32)

Country Link
US (2) US11845808B2 (enExample)
EP (2) EP4613761A3 (enExample)
JP (2) JP7441955B2 (enExample)
KR (1) KR20220141807A (enExample)
CN (5) CN118027153A (enExample)
AR (1) AR121070A1 (enExample)
AU (1) AU2021207653A1 (enExample)
CA (1) CA3167751A1 (enExample)
CL (2) CL2022001893A1 (enExample)
CO (1) CO2022009931A2 (enExample)
CR (1) CR20220332A (enExample)
DK (1) DK4090670T3 (enExample)
DO (1) DOP2022000147A (enExample)
EC (1) ECSP22063238A (enExample)
ES (1) ES3036287T3 (enExample)
FI (1) FI4090670T3 (enExample)
HR (1) HRP20250769T1 (enExample)
HU (1) HUE072238T2 (enExample)
IL (1) IL294680A (enExample)
JO (1) JOP20220169A1 (enExample)
LT (1) LT4090670T (enExample)
MA (1) MA58373B1 (enExample)
MX (1) MX2022008741A (enExample)
PE (1) PE20230370A1 (enExample)
PH (1) PH12022551750A1 (enExample)
PL (1) PL4090670T3 (enExample)
PT (1) PT4090670T (enExample)
RS (1) RS66991B1 (enExample)
SI (1) SI4090670T1 (enExample)
SM (1) SMT202500254T1 (enExample)
TW (2) TWI882061B (enExample)
WO (1) WO2021146441A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
TW202332683A (zh) * 2021-07-14 2023-08-16 美商健生生物科技公司 介白素－２３受體之肽抑制劑
EP4373800A4 (en) * 2021-07-23 2025-10-15 Blackstone Therapeutics Llc PROCESS FOR THE PREPARATION OF HEXAHYDROCANNABINOL
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
IL314629A (en) 2022-02-01 2024-09-01 Janssen Pharmaceutica Nv Peptide inhibitors of the interleukin-23 receptor and pharmaceutical preparations thereof
US20250206692A1 (en) * 2022-03-14 2025-06-26 Colorado Chromatography, Llc Hydrogenation of cannabigerol and cannabichromene
CA3260606A1 (en) 2022-06-30 2024-01-04 Sanofi NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
WO2024110477A2 (en) * 2022-11-21 2024-05-30 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
WO2024114762A1 (zh) * 2022-11-30 2024-06-06 上海翰森生物医药科技有限公司 一种多肽抑制剂、其制备方法和应用
WO2024155553A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Lipidated peptide inhibitors of interleukin-23 receptor
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
IL322423A (en) 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN120826233A (zh) * 2023-03-03 2025-10-21 詹森药业有限公司 用于治疗银屑病的白介素-23受体拮抗剂肽
CN121443624A (zh) * 2023-05-04 2026-01-30 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) * 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025163534A1 (en) 2024-01-31 2025-08-07 Janssen Pharmaceutica Nv Crystal form of a peptide inhibitor of interleukin-23 receptor
WO2025243217A1 (en) * 2024-05-22 2025-11-27 Janssen Pharmaceutica Nv Crystal forms of peptide molecules
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026816A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026046292A1 (zh) * 2024-08-28 2026-03-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂的药物组合物及其制备方法和用途
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途
CN120905324A (zh) * 2025-10-10 2025-11-07 北京元延医药科技股份有限公司 白细胞介素-23受体肽抑制剂及其手性中间体的制法

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
JPH02306947A (ja) 1989-05-01 1990-12-20 Monsanto Co キラルβ―アミノ酸の製造方法
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
US5569741A (en) 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
CZ168194A3 (en) 1992-11-12 1994-12-15 Biomeasure Opioid peptides
AU673731B2 (en) 1993-06-03 1996-11-21 Banyu Pharmaceutical Co., Ltd. Novel endothelin antagonistic peptide
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US5942492A (en) 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5993811A (en) 1997-02-03 1999-11-30 Biology Associates, Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
JP2001509493A (ja) 1997-07-11 2001-07-24 インナーダイン， インコーポレイテッド 放射送達構造体の調製およびシール化のための方法およびシステム
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
AU750175B2 (en) 1997-11-24 2002-07-11 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US8038984B2 (en) 1998-06-20 2011-10-18 Washington University Membrane-permeant peptide complexes for treatment of sepsis
US6248057B1 (en) 1998-07-28 2001-06-19 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
ES2231179T3 (es) 1999-04-12 2005-05-16 Aventis Pharma Limited Compuestos de heteroarilo biciclicos sustituidos como antagonistas de la integrina.
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
KR100983997B1 (ko) 2001-01-09 2010-09-28 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
WO2004011650A2 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
US20040176293A1 (en) 2002-12-18 2004-09-09 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
AU2004231122B2 (en) 2003-04-15 2010-04-08 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
US20060030053A1 (en) 2003-12-19 2006-02-09 Applera Corporation Methods and systems for protein and peptide evidence assembly
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
US20070197430A1 (en) 2004-06-24 2007-08-23 Jonathan Baell Conjugates And Therapeutic Uses Thereof
EP1799705A4 (en) 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006058539A2 (en) 2004-11-30 2006-06-08 Gastrotech Pharma A/S Growth hormone secretagogue receptor 1a ligands
US20100183617A1 (en) 2005-02-23 2010-07-22 University Of Virginia Patent Foundation Compositions and methods for regulating sas1r
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US8076306B2 (en) 2006-04-12 2011-12-13 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
GB0610395D0 (en) 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20080019913A1 (en) 2006-07-07 2008-01-24 University Of Arizona Office Of Technology Transfer Enkepahlin analogs with improved bioavailability
KR101399175B1 (ko) 2006-07-21 2014-06-19 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 항염증성 및 항알레르기성 시클릭 펩티드
WO2008045252A2 (en) 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US8313950B2 (en) 2007-05-21 2012-11-20 The Ohio State University Research Foundation Hepcidins as biomarkers for impending lupus nephritis flare
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
JP2011501941A (ja) 2007-07-06 2011-01-20 バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ Ｉｌ−２３レセプターのアンタゴニストおよびその使用
CN101358201A (zh) 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
GR1006896B (el) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2009039185A1 (en) 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
US8435941B2 (en) 2008-12-05 2013-05-07 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
CA2758264A1 (en) 2009-04-08 2010-10-14 Takeda Pharmaceutical Company Limited Neuromedin u derivative
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CA2787331A1 (en) 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
JP2011231085A (ja) 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
US20130236977A1 (en) 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2444101A1 (en) 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
EP2668199B1 (en) 2011-01-27 2017-09-06 Ramot at Tel Aviv University, Ltd. Glycogen synthase kinase-3 inhibitors
CA2839408A1 (en) 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
BR112014013697A2 (pt) 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
WO2013177432A1 (en) 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
US9024044B2 (en) 2012-06-14 2015-05-05 Ajinomoto Co., Inc. Heteroarylcarboxylic acid ester derivative
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
WO2014127316A2 (en) 2013-02-15 2014-08-21 Srx Cardio, Llc Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
RU2732440C2 (ru) 2013-06-24 2020-09-16 Кэнбас Ко., Лтд. Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями
WO2014210056A1 (en) 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
US20160235807A1 (en) 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2015112700A1 (en) 2014-01-22 2015-07-30 Wisconsin Alumni Research Foundation Alpha/beta-peptide mimics of z-domain peptides
EP3129040A4 (en) 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2015200916A2 (en) 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
EP3240799B1 (en) 2014-12-29 2021-03-31 The Regents of the University of California S-alkylated hepcidin peptides and methods of making and using thereof
US20160199437A1 (en) 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20160228491A1 (en) 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
WO2016195663A1 (en) 2015-06-02 2016-12-08 Stealth Peptides International, Inc. Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof
WO2016200364A1 (en) 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2018022917A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Disulfide-rich peptide libraries and methods of use thereof
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2018089693A2 (en) 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
JP7100034B2 (ja) 2016-12-06 2022-07-12 シュティヒティング・ヴォール・デ・テクニシェ・ヴェテンシャッペン 多環式ペプチド及びそれらの調製方法
WO2018136646A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN113631569A (zh) 2019-03-28 2021-11-09 领导医疗有限公司 用于合成β-高氨基酸的方法
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021007433A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PH12022550510A1 (en) 2019-09-03 2023-09-04 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
CA3166637A1 (en) 2020-01-10 2021-07-15 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with .alpha.4.beta.7 integrin antagonists
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021315564A1 (en) 2020-07-28 2023-02-09 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
US20240226225A1 (en) 2021-04-01 2024-07-11 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2022249095A1 (en) 2021-04-01 2023-10-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
IL309166A (en) 2021-06-14 2024-02-01 Protagonist Therapeutics Inc Pasidine mimesis for the treatment of hereditary hemochromatosis

Also Published As

Publication number Publication date
SMT202500254T1 (it) 2025-09-12
LT4090670T (lt) 2025-08-11
MX2022008741A (es) 2022-10-03
HUE072238T2 (hu) 2025-11-28
ECSP22063238A (es) 2022-09-30
CR20220332A (es) 2022-11-28
JP2023139158A (ja) 2023-10-03
PL4090670T3 (pl) 2025-07-28
HRP20250769T1 (hr) 2025-08-29
CN118005736A (zh) 2024-05-10
TW202140517A (zh) 2021-11-01
JOP20220169A1 (ar) 2023-01-30
CL2024004039A1 (es) 2025-05-09
AU2021207653A1 (en) 2022-08-04
EP4090670A1 (en) 2022-11-23
TWI882061B (zh) 2025-05-01
EP4613761A9 (en) 2025-10-22
JP7441955B2 (ja) 2024-03-01
DK4090670T3 (da) 2025-06-30
PE20230370A1 (es) 2023-03-06
CN118063554A (zh) 2024-05-24
EP4090670A4 (en) 2024-11-20
CN118005737A (zh) 2024-05-10
KR20220141807A (ko) 2022-10-20
BR112022013957A2 (pt) 2022-10-11
ES3036287T3 (en) 2025-09-17
US20210261622A1 (en) 2021-08-26
WO2021146441A1 (en) 2021-07-22
US20240150405A1 (en) 2024-05-09
CN118027153A (zh) 2024-05-14
DOP2022000147A (es) 2023-01-15
CN115298196A (zh) 2022-11-04
EP4613761A2 (en) 2025-09-10
MA58373B1 (fr) 2025-07-31
EP4090670B1 (en) 2025-06-04
PT4090670T (pt) 2025-07-29
TW202515892A (zh) 2025-04-16
RS66991B1 (sr) 2025-08-29
AR121070A1 (es) 2022-04-13
IL294680A (en) 2022-09-01
PH12022551750A1 (en) 2023-11-13
US11845808B2 (en) 2023-12-19
CL2022001893A1 (es) 2023-03-03
SI4090670T1 (sl) 2025-08-29
CO2022009931A2 (es) 2022-10-21
CA3167751A1 (en) 2021-07-22
JP2023511552A (ja) 2023-03-20
EP4613761A3 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
FI4090670T3 (fi) Interleukiini-23-reseptorin peptidiestäjiä ja niiden käyttö tulehdussairauksien hoidossa
IL258253A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
UA86037C2 (ru) Бициклические [3.1.0] производные, как ингибиторы переносчика глицина
JPH02184697A (ja) ブラジキニンアンタゴニスト作用を有するペプチド
MX2023012178A (es) Compuesto de peptído corto de prolina modificado con anillo y uso del mismo.
JOP20210259A1 (ar) مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني
EA201991786A1 (ru) Способы введения некоторых vmat2-ингибиторов
CO6241137A2 (es) Antagonistas ciclicos de peptido cxcr4
EP1451163A4 (en) 3-AMIDO-1,2-BENZOXOXAZOLE DERIVATIVES, METHOD OF MANUFACTURE AND ITS USE
SK70499A3 (en) Heptapeptide analogue, pharmaceutical composition contaning the same, process for the preparation of heptapeptide analogue and its use, process for the preparation of the pharmaceutical composition contaning said analogue
WO2012074437A3 (ru) Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
PH12021550675A1 (en) Sustained delivery of angiopoetin-like 3 polypeptides
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
NO20053398D0 (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
US9611297B1 (en) Compositions and methods for the treatment of cast nephropathy and related conditions
CY1125690T1 (el) Αντιμυκητιασικα μεσα με ενισχυμενηδραστηριοτητα σε οξινο ρη
RU2012108179A (ru) Новый пептид и его применение
CN1953989A (zh) 作为细胞抑制剂的在7位与环肽缀合的喜树碱
MX2019001153A (es) Peptidos ciclicos como antagonistas del receptor c5a.
JP5190957B2 (ja) アミロイドβ線維化阻害ペプチド
MX2021010552A (es) Nuevo peptido y uso del mismo.
JP2019506840A5 (enExample)
AU691246B2 (en) Cyclic neurokinin A antagonists
MX2025010360A (es) Peptidos antagonistas del receptor de interleucina-23 para usar en el tratamiento de la psoriasis
ATE435650T1 (de) 2,5-disubstituierte phenylmethanonderivative als glycintransporter-1-inhibitoren (glyt-1) zur behandlung von neurologischen und neuropsychiatrischen störungen